Intermittent dosing with rapamycin selectively breaks the cascade of inflammatory events that
follow cellular senescence, a phenomena in which cells cease to divide in response to DNA damaging agents, including many chemotherapies.
But then, upon reading the article mentionned by Deleo, I spotted the
following: «So 20 - employee Unity now has a potential drug that David [the CEO] said could land in human clinical trials within two years, venture cash, respected executives, intellectual property blanketing
cellular senescence -LRB-...)»